Medical Services

Rare blood malignancies known as myeloproliferative neoplasms (MPNs) start in the bone marrow, where aberrant signals lead to too abundant one or another type of blood cell synthesis. Unlike other haematologic malignancies, MPNs often advance gradually but can cause major problems such as blood clots, haemorrhage, or a change into acute leukaemia.
Polycythaemia Vera (PV) leads to too many red blood cells; Essential Thrombocythemia (ET) results in an excess of platelets; and Myelofibrosis (MF) causes scarring in the bone marrow, which affects blood cell production. Headaches, tiredness, night sweats, itching, an enlarged spleen, and a propensity to bleed easily could all be symptoms.
Blood tests, bone marrow biopsies, and molecular testing are used in diagnosis to identify particular mutations, including JAK2, CALR, or MPL, therefore guiding treatment and confirming the kind of MPN.
Treatments, including targeted therapy (e.g., JAK inhibitors), aspirin, phlebotomy, or chemotherapy, can efficiently control symptoms and lower risks, thereby improving patient outcomes and quality of life even if there is no clear cure for MPNs except in rare circumstances.